Drug intelligence / Profile preview

megestrol acetate + mitomycin-c

Development stage: Unknown
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of megestrol acetate (a synthetic progestin) and mitomycin-C (an antineoplastic antibiotic). This regimen was studied primarily for the treatment of breast cancer that was refractory to hormonal and combination chemotherapy. In clinical trials from the late 1970s, the combination showed a response rate of approximately 27% (4% complete remission, 23% partial remission) with a median response duration of 7 months in patients with advanced breast cancer who had failed previous treatments.

Targets

PR (Progesterone receptor)AR (Adrenergic receptors)DNA

Beyond the preview

Go deeper on megestrol acetate + mitomycin-c.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on megestrol acetate + mitomycin-c.

Explore the full profile